Research and Markets has announced the addition of the "Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Pipeline Insights, 2017" report to their offering.

Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors.

This report covers the product profiles in various stages of development including Discovery, Pre - clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors.

This report also assesses the Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Key Topics Covered:

  1. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Overview
  2. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Disease Associated
  3. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Pipeline Therapeutics
  4. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Therapeutics under Development by Companies
  5. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Filed and Phase III Products
  6. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Phase II Products
  7. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Phase I and IND Filed Products
  8. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors Discovery and Pre-Clinical Stage Products
  9. Drug Candidate Profiles
  10. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Therapeutics Assessment
  11. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Discontinued Products
  12. Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors - Dormant Products
  13. Companies Involved in Therapeutics Development for Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitors
  14. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/67chzx/type_1